Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Generation of two human isogenic iPSC lines from fetal dermal fibroblasts.

Tandon R, Brändl B, Baryshnikova N, Landshammer A, Steenpaß L, Keminer O, Pless O, Müller FJ.

Stem Cell Res. 2018 Oct 12;33:120-124. doi: 10.1016/j.scr.2018.10.004. [Epub ahead of print]

2.

Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy.

Kraft C, Boya P, Codogno P, Elazar Z, Eskelinen EL, Farrés J, Kirkin V, Jungbluth H, Martinez A, Pless O, Primard C, Proikas-Cezanne T, Simonsen A, Reggiori F.

Autophagy. 2018 Sep 13:1-5. doi: 10.1080/15548627.2018.1515532. [Epub ahead of print]

PMID:
30176150
3.

Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring.

Stoessel D, Stellmann JP, Willing A, Behrens B, Rosenkranz SC, Hodecker SC, Stürner KH, Reinhardt S, Fleischer S, Deuschle C, Maetzler W, Berg D, Heesen C, Walther D, Schauer N, Friese MA, Pless O.

Front Hum Neurosci. 2018 Jun 4;12:226. doi: 10.3389/fnhum.2018.00226. eCollection 2018.

4.

T Cell Phenotype and T Cell Receptor Repertoire in Patients with Major Depressive Disorder.

Patas K, Willing A, Demiralay C, Engler JB, Lupu A, Ramien C, Schäfer T, Gach C, Stumm L, Chan K, Vignali M, Arck PC, Friese MA, Pless O, Wiedemann K, Agorastos A, Gold SM.

Front Immunol. 2018 Feb 20;9:291. doi: 10.3389/fimmu.2018.00291. eCollection 2018.

5.

A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).

Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S, Reinhardt S, Gellissen S, Weissflog G, Faizy TD, Werz O, Fleischer S, Vaas LAI, Herrmann F, Pless O, Martin R, Heesen C.

J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):330-338. doi: 10.1136/jnnp-2017-317101. Epub 2017 Dec 16.

PMID:
29248894
6.

Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation.

Ufer F, Vargas P, Engler JB, Tintelnot J, Schattling B, Winkler H, Bauer S, Kursawe N, Willing A, Keminer O, Ohana O, Salinas-Riester G, Pless O, Kuhl D, Friese MA.

Sci Immunol. 2016 Sep 23;1(3):eaaf8665. doi: 10.1126/sciimmunol.aaf8665.

PMID:
28783680
7.

Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.

Prondzynski M, Krämer E, Laufer SD, Shibamiya A, Pless O, Flenner F, Müller OJ, Münch J, Redwood C, Hansen A, Patten M, Eschenhagen T, Mearini G, Carrier L.

Mol Ther Nucleic Acids. 2017 Jun 16;7:475-486. doi: 10.1016/j.omtn.2017.05.008. Epub 2017 May 17.

8.

Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience.

De Sousa PA, Steeg R, Wachter E, Bruce K, King J, Hoeve M, Khadun S, McConnachie G, Holder J, Kurtz A, Seltmann S, Dewender J, Reimann S, Stacey G, O'Shea O, Chapman C, Healy L, Zimmermann H, Bolton B, Rawat T, Atkin I, Veiga A, Kuebler B, Serano BM, Saric T, Hescheler J, Brüstle O, Peitz M, Thiele C, Geijsen N, Holst B, Clausen C, Lako M, Armstrong L, Gupta SK, Kvist AJ, Hicks R, Jonebring A, Brolén G, Ebneth A, Cabrera-Socorro A, Foerch P, Geraerts M, Stummann TC, Harmon S, George C, Streeter I, Clarke L, Parkinson H, Harrison PW, Faulconbridge A, Cherubin L, Burdett T, Trigueros C, Patel MJ, Lucas C, Hardy B, Predan R, Dokler J, Brajnik M, Keminer O, Pless O, Gribbon P, Claussen C, Ringwald A, Kreisel B, Courtney A, Allsopp TE.

Stem Cell Res. 2017 Apr;20:105-114. doi: 10.1016/j.scr.2017.03.002. Epub 2017 Mar 7.

9.

A screening strategy for the discovery of drugs that reduce C/EBPβ-LIP translation with potential calorie restriction mimetic properties.

Zaini MA, Müller C, Ackermann T, Reinshagen J, Kortman G, Pless O, Calkhoven CF.

Sci Rep. 2017 Feb 15;7:42603. doi: 10.1038/srep42603.

10.

Short-term molecular and physiological responses to heat stress in neritic copepods Acartia tonsa and Eurytemora affinis.

Rahlff J, Peters J, Moyano M, Pless O, Claussen C, Peck MA.

Comp Biochem Physiol A Mol Integr Physiol. 2017 Jan;203:348-358. doi: 10.1016/j.cbpa.2016.11.001. Epub 2016 Nov 5.

PMID:
27825870
11.

Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.

Briken S, Rosenkranz SC, Keminer O, Patra S, Ketels G, Heesen C, Hellweg R, Pless O, Schulz KH, Gold SM.

J Neuroimmunol. 2016 Oct 15;299:53-58. doi: 10.1016/j.jneuroim.2016.08.007. Epub 2016 Aug 5.

PMID:
27725121
12.

IL-17 production by CSF lymphocytes as a biomarker for cerebral vasculitis.

Thom V, Schmid S, Gelderblom M, Hackbusch R, Kolster M, Schuster S, Thomalla G, Keminer O, Pleß O, Bernreuther C, Glatzel M, Wegscheider K, Gerloff C, Magnus T, Tolosa E.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 21;3(2):e214. doi: 10.1212/NXI.0000000000000214. eCollection 2016 Apr.

13.

Molecular Characterization of the NLRC4 Expression in Relation to Interleukin-18 Levels.

Zeller T, Haase T, Müller C, Riess H, Lau D, Zeller S, Krause J, Baumert J, Pless O, Dupuis J, Wild PS, Eleftheriadis M, Waldenberger M, Zeilinger S, Ziegler A, Peters A, Tiret L, Proust C, Marzi C, Munzel T, Strauch K, Prokisch H, Lackner KJ, Herder C, Thorand B, Benjamin EJ, Blankenberg S, Koenig W, Schnabel RB.

Circ Cardiovasc Genet. 2015 Oct;8(5):717-26. doi: 10.1161/CIRCGENETICS.115.001079. Epub 2015 Sep 11.

14.

A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function.

Stürner KH, Borgmeyer U, Schulze C, Pless O, Martin R.

J Immunol. 2014 Nov 1;193(9):4439-47. doi: 10.4049/jimmunol.1303077. Epub 2014 Sep 26.

15.

Functional role of the interaction between polysialic acid and myristoylated alanine-rich C kinase substrate at the plasma membrane.

Theis T, Mishra B, von der Ohe M, Loers G, Prondzynski M, Pless O, Blackshear PJ, Schachner M, Kleene R.

J Biol Chem. 2013 Mar 1;288(9):6726-42. doi: 10.1074/jbc.M112.444034. Epub 2013 Jan 17.

16.

A differential proteome screening system for post-translational modification-dependent transcription factor interactions.

Pless O, Kowenz-Leutz E, Dittmar G, Leutz A.

Nat Protoc. 2011 Mar;6(3):359-64. doi: 10.1038/nprot.2011.303. Epub 2011 Feb 24.

PMID:
21372816
17.

Crosstalk between phosphorylation and multi-site arginine/lysine methylation in C/EBPs.

Leutz A, Pless O, Lappe M, Dittmar G, Kowenz-Leutz E.

Transcription. 2011 Jan-Feb;2(1):3-8. doi: 10.4161/trns.2.1.13510.

18.

Crosstalk between C/EBPbeta phosphorylation, arginine methylation, and SWI/SNF/Mediator implies an indexing transcription factor code.

Kowenz-Leutz E, Pless O, Dittmar G, Knoblich M, Leutz A.

EMBO J. 2010 Mar 17;29(6):1105-15. doi: 10.1038/emboj.2010.3. Epub 2010 Jan 28.

19.

Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1.

Lausen J, Pless O, Leonard F, Kuvardina ON, Koch B, Leutz A.

J Biol Chem. 2010 Feb 19;285(8):5338-46. doi: 10.1074/jbc.M109.030296. Epub 2009 Dec 22.

20.

G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta.

Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ, Leutz A.

J Biol Chem. 2008 Sep 26;283(39):26357-63. doi: 10.1074/jbc.M802132200. Epub 2008 Jul 21.

Supplemental Content

Support Center